VICTORIA, Feb. 23, 2017 /CNW/ - Emerald Health
Therapeutics Inc. (TSXV: EMH) ("Emerald" or the "Company") is
pleased to announce that it has been notified by the TSX Venture
Exchange ("TSXV") that it achieved a ranking of 3rd
Place in the Clean Technology & Life Science sector of the 2017
TSX Venture 50®.
"Emerald is thrilled to be part of such an accomplished group of
companies, and recognized for its achievements in 2016. While last
year was one of transformation for the whole industry, we expect
2017 to be a year of considerable progress for Emerald as we embark
on a series of aggressive growth initiatives (see corporate update
here). We would like to thank our staff and shareholders for
continued support and belief in the future of Emerald," stated
Avtar Dhillon, MD, Executive
Chairman.
The 2017 TSX Venture 50® is a ranking of the top performers
listed on the TSXV, divided into five industry sectors. The
companies are selected based on three equally weighted criteria:
market capitalization growth, share price appreciation and trading
volume. The TSXV has created a video profile on Emerald, which will
be distributed on February 23, 2017,
along with the official announcement of the winners.
Join us on our journey of enhancing health through
cannabis science.
For more information, explore our website and investor
presentation here.
Emerald Health Therapeutics Inc.
Emerald Health Therapeutics, Inc. operates primarily through
Emerald Health Botanicals Inc. ("Botanicals"), a wholly owned
subsidiary of the Company and a Licensed Producer under the Access
to Cannabis for Medical Purposes Regulations (the "ACMPR").
Botanicals is authorized to cultivate and sell both dried medical
cannabis flowers and medical cannabis oils in Canada. Botanicals currently operates an
indoor cultivation facility in Victoria,
British Columbia, and plans to construct a much larger
purpose built hybrid greenhouse facility on 32 acres in metro
Vancouver. Botanicals prides
itself on being one of Canada's
most medically focused licensed producers and on having one of the
industry's most qualified management teams with respect to
pharmaceutical drug discovery, development and distribution.
Botanicals intends to capture unique niches in both the medical and
future adult use cannabis markets through its proprietary strains,
defensible intellectual property, and superb client experience.
"Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
SOURCE Emerald Health Therapeutics, Inc.